share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

Needham再次买入blueprint medicines,维持133美元的目标价
Benzinga ·  10/30 19:50  · 评级/大行评级

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $133 price target.

Needham分析师Ami Fadia重申对blueprint medicines(纳斯达克:BPMC)的买入评级,并维持目标股价133美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发